400 related articles for article (PubMed ID: 23323877)
1. A double-blind, double-dummy, randomized, placebo-controlled trial to evaluate the effect of statin therapy on triglyceride levels in Mexican hypertriglyceridemic patients.
Talavera JO; Martinez G; Cervantes JL; Marin JA; Rodriguez-Briones I; Gonzalez JG; Ocampo R; Sanchez-Mijangos H; Bernal-Rosales LP; Polanco A
Curr Med Res Opin; 2013 Apr; 29(4):379-86. PubMed ID: 23323877
[TBL] [Abstract][Full Text] [Related]
2. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
3. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
Ballantyne CM; Pitt B; Loscalzo J; Cain VA; Raichlen JS
Am J Cardiol; 2013 Feb; 111(4):506-9. PubMed ID: 23237107
[TBL] [Abstract][Full Text] [Related]
4. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
Schwartz GG; Bolognese MA; Tremblay BP; Caplan R; Hutchinson H; Raza A; Cressman M
Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813
[TBL] [Abstract][Full Text] [Related]
6. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
[TBL] [Abstract][Full Text] [Related]
7. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
Roth EM; McKenney JM; Kelly MT; Setze CM; Carlson DM; Gold A; Stolzenbach JC; Williams LA; Jones PH
Am J Cardiovasc Drugs; 2010; 10(3):175-86. PubMed ID: 20524719
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
[TBL] [Abstract][Full Text] [Related]
10. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
Roth EM; Rosenson RS; Jones PH; Davidson MH; Kelly MT; Setze CM; Lele A; Thakker K
J Clin Lipidol; 2012; 6(6):534-44. PubMed ID: 23312049
[TBL] [Abstract][Full Text] [Related]
11. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
Weinstein DL; Williams LA; Carlson DM; Kelly MT; Burns KM; Setze CM; Lele A; Stolzenbach JC
Clin Ther; 2013 Aug; 35(8):1186-98. PubMed ID: 23891363
[TBL] [Abstract][Full Text] [Related]
13. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
[TBL] [Abstract][Full Text] [Related]
14. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
Farnier M; Averna M; Missault L; Vaverkova H; Viigimaa M; Massaad R; Vandormael K; Johnson-Levonas AO; Brudi P
Int J Clin Pract; 2009 Apr; 63(4):547-59. PubMed ID: 19222610
[TBL] [Abstract][Full Text] [Related]
15. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.
Wolffenbuttel BH; Franken AA; Vincent HH;
J Intern Med; 2005 Jun; 257(6):531-9. PubMed ID: 15910557
[TBL] [Abstract][Full Text] [Related]
16. Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy.
Shepherd J; Packard C; Littlejohn TW; Walker J; Stein EA; Smith K; Kallend D; Blasetto JW
Curr Med Res Opin; 2004 Oct; 20(10):1571-8. PubMed ID: 15462690
[TBL] [Abstract][Full Text] [Related]
17. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
Jones PH; Davidson MH; Kashyap ML; Kelly MT; Buttler SM; Setze CM; Sleep DJ; Stolzenbach JC
Atherosclerosis; 2009 May; 204(1):208-15. PubMed ID: 18996523
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Bays H; Rhyne J; Stein E; Rotenberg K; Doyle R
Clin Ther; 2005 Jun; 27(6):715-27. PubMed ID: 16117978
[TBL] [Abstract][Full Text] [Related]
20. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
